{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:16:09Z","timestamp":1790651769482,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":65,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Nasopharyngeal carcinoma (NPC) in advanced stages often has a poor prognosis due to distant metastasis, yet the distribution characteristics and anti-metastatic mechanisms of tumor-infiltrating B cells (TIL-B) remain unclear. In this study, single-cell RNA sequencing combined with multiplex immunofluorescence revealed that B cells were highly enriched in non-metastatic NPC and formed complete tertiary lymphoid structures (TLS), whereas TLS was absent in metastatic NPC. Functional assays in vitro and in vivo showed that TIL-B and their conditioned medium significantly inhibited NPC cell proliferation, migration, and epithelial-mesenchymal transition (EMT), while inducing apoptosis; in humanized mouse models, TIL-B suppressed subcutaneous tumor growth and lung metastasis, whereas B cell depletion accelerated tumor progression. Mechanistically, TIL-B secreted IL-12, IFN-\u03b3, TNF-\u03b1, and CXCL13. Among them, IL-12 upregulated E-cadherin and downregulated N-cadherin and Vimentin, thereby blocking EMT and inhibiting vasculogenic mimicry (VM); CXCL13 may promote TLS formation and enhance local immune responses. Through the dual pathways of \u201c IL-12-EMT\/VM inhibition\u201d and \u201cCXCL13-TLS construction,\u201d TIL-B cooperatively restrains tumor invasion and metastasis, building a multidimensional immune defense system. This study demonstrates that TIL-B play an important regulatory role in anti-tumor immunity in NPC and suggests their therapeutic potential, providing a rationale for the development of B cell-based or TLS-targeted immunotherapeutic strategies.<\/jats:p>","DOI":"10.1038\/s41419-026-08940-6","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T16:14:03Z","timestamp":1780416843000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Tumor-infiltrating B cells inhibit nasopharyngeal carcinoma metastasis"],"prefix":"10.1038","volume":"17","author":[{"given":"Jing","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangzhou","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinglong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangying","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3168-0672","authenticated-orcid":false,"given":"Lin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"8940_CR1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","volume":"394","author":"YP Chen","year":"2019","unstructured":"Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet. 2019;394:64\u201380.","journal-title":"Lancet"},{"key":"8940_CR2","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","volume":"577","author":"BA Helmink","year":"2020","unstructured":"Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020;577:549\u201355.","journal-title":"Nature"},{"key":"8940_CR3","doi-asserted-by":"crossref","unstructured":"Li JP, Wu CY, Chen MY, Liu SX, Yan SM, Kang YF, et al. PD-1(+)CXCR5(-)CD4(+) Th-CXCL13 cell subset drives B cells into tertiary lymphoid structures of nasopharyngeal carcinoma. J Immunother Cancer. 2021;9:e002101.","DOI":"10.1136\/jitc-2020-002101"},{"key":"8940_CR4","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1158\/2326-6066.CIR-17-0075","volume":"5","author":"TC Bruno","year":"2017","unstructured":"Bruno TC, Ebner PJ, Moore BL, Squalls OG, Waugh KA, Eruslanov EB, et al. Antigen-presenting intratumoral B cells affect CD4(+) TIL phenotypes in non-small cell lung cancer patients. Cancer Immunol Res. 2017;5:898\u2013907.","journal-title":"Cancer Immunol Res"},{"key":"8940_CR5","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41577-019-0257-x","volume":"20","author":"GV Sharonov","year":"2020","unstructured":"Sharonov GV, Serebrovskaya EO, Yuzhakova DV, Britanova OV, Chudakov DM. B cells, plasma cells and antibody repertoires in the tumour microenvironment. Nat Rev Immunol. 2020;20:294\u2013307.","journal-title":"Nat Rev Immunol"},{"key":"8940_CR6","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","volume":"577","author":"R Cabrita","year":"2020","unstructured":"Cabrita R, Lauss M, Sanna A, Donia M, Skaarup Larsen M, Mitra S, et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature. 2020;577:561\u20135.","journal-title":"Nature"},{"key":"8940_CR7","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.7150\/ijbs.79482","volume":"19","author":"Y Xu","year":"2023","unstructured":"Xu Y, Mao Y, Lv Y, Tang W, Xu J. B cells in tumor metastasis: friend or foe? Int J Biol Sci. 2023;19:2382\u201393.","journal-title":"Int J Biol Sci"},{"key":"8940_CR8","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41586-019-1906-8","volume":"577","author":"F Petitprez","year":"2020","unstructured":"Petitprez F, de Reynies A, Keung EZ, Chen TW, Sun CM, Calderaro J, et al. B cells are associated with survival and immunotherapy response in sarcoma. Nature. 2020;577:556\u201360.","journal-title":"Nature"},{"key":"8940_CR9","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.annonc.2023.12.011","volume":"35","author":"N Gavrielatou","year":"2024","unstructured":"Gavrielatou N, Fortis E, Spathis A, Anastasiou M, Economopoulou P, Foukas GRP, et al. B-cell infiltration is associated with survival outcomes following programmed cell death protein 1 inhibition in head and neck squamous cell carcinoma. Ann Oncol. 2024;35:340\u201350.","journal-title":"Ann Oncol"},{"key":"8940_CR10","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2019104063","volume":"39","author":"SZ Wu","year":"2020","unstructured":"Wu SZ, Roden DL, Wang C, Holliday H, Harvey K, Cazet AS, et al. Stromal cell diversity associated with immune evasion in human triple-negative breast cancer. EMBO J. 2020;39:e104063.","journal-title":"EMBO J"},{"key":"8940_CR11","doi-asserted-by":"publisher","DOI":"10.1126\/science.adj4857","volume":"384","author":"J Ma","year":"2024","unstructured":"Ma J, Wu Y, Ma L, Yang X, Zhang T, Song G, et al. A blueprint for tumor-infiltrating B cells across human cancers. Science. 2024;384:eadj4857.","journal-title":"Science"},{"key":"8940_CR12","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41580-018-0080-4","volume":"20","author":"A Dongre","year":"2019","unstructured":"Dongre A, Weinberg RA. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2019;20:69\u201384.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"8940_CR13","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41568-019-0144-6","volume":"19","author":"C Sautes-Fridman","year":"2019","unstructured":"Sautes-Fridman C, Petitprez F, Calderaro J, Fridman WH. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer. 2019;19:307\u201325.","journal-title":"Nat Rev Cancer"},{"key":"8940_CR14","doi-asserted-by":"crossref","unstructured":"Gu-Trantien C, Migliori E, Buisseret L, de Wind A, Brohee S, Garaud S, et al. CXCL13-producing TFH cells link immune suppression and adaptive memory in human breast cancer. JCI Insight. 2017;2:e91487.","DOI":"10.1172\/jci.insight.91487"},{"key":"8940_CR15","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.immuni.2013.10.003","volume":"39","author":"G Bindea","year":"2013","unstructured":"Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013;39:782\u201395.","journal-title":"Immunity"},{"key":"8940_CR16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ccell.2024.11.011","volume":"43","author":"CT Kureshi","year":"2025","unstructured":"Kureshi CT, Dougan SK. Cytokines in cancer. Cancer Cell. 2025;43:15\u201335.","journal-title":"Cancer Cell"},{"key":"8940_CR17","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.immuni.2019.01.006","volume":"50","author":"CS Pai","year":"2019","unstructured":"Pai CS, Huang JT, Lu X, Simons DM, Park C, Chang A, et al. Clonal deletion of tumor-specific T cells by interferon-gamma confers therapeutic resistance to combination immune checkpoint blockade. Immunity. 2019;50:477\u2013492 e478.","journal-title":"Immunity"},{"key":"8940_CR18","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/j.cell.2017.05.005","volume":"169","author":"AE Overacre-Delgoffe","year":"2017","unstructured":"Overacre-Delgoffe AE, Chikina M, Dadey RE, Yano H, Brunazzi EA, Shayan G, et al. Interferon-gamma drives T(reg) fragility to promote anti-tumor immunity. Cell. 2017;169:1130\u201341.e1111.","journal-title":"Cell"},{"key":"8940_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.semcancer.2024.04.001","volume":"101","author":"YE Zhang","year":"2024","unstructured":"Zhang YE, Stuelten CH. Alternative splicing in EMT and TGF-beta signaling during cancer progression. Semin Cancer Biol. 2024;101:1\u201311.","journal-title":"Semin Cancer Biol"},{"key":"8940_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102146","volume":"6","author":"T Xia","year":"2025","unstructured":"Xia T, Yin H, Zhu Q, Zhang K, Xie H, Shan Y, et al. DDX5 super-enhancer promotes vasculogenic mimicry formation and metastasis in nasopharyngeal carcinoma by enhancing ADAM10 transcription. Cell Rep Med. 2025;6:102146.","journal-title":"Cell Rep Med"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08940-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08940-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08940-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T13:02:47Z","timestamp":1786021367000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08940-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8940"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08940-6","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]},"assertion":[{"value":"28 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"689"}}